Breaking Finance News

Liberum Capital upgraded Shire PLC (ADR) (NDAQ:SHPG) from Hold to Buy in a report released today.

Liberum Capital has upgraded Shire PLC (ADR) (NDAQ:SHPG) from Hold to Buy in a report released on 11/14/2017.

Previously on 10/19/2017, FBR Capital reported on Shire PLC (ADR) (NDAQ:SHPG) increased the target price from $0.00 to $201.00. At the time, this indicated a possible upside of 0.36%.

Yesterday Shire PLC (ADR) (NDAQ:SHPG) traded 2.84% higher at $138.94. The company’s 50-day moving average is $152.36 and its 200-day moving average is $163.12. The last closing price is down -12.84% from the 200-day moving average, compared to the S&P 500 which has increased 0.02% over the same time period. 2,091,441 shares of the stock traded hands, up from an average trading volume of 1,167,350

See Chart Below

Shire PLC (ADR) (NDAQ:SHPG)

Shire PLC (ADR) has a 52 week low of $137.80 and a 52 week high of $192.64 with a P/E ratio of 63.61 The company’s market cap is currently $0.

A total of 14 analysts have released a report on Shire PLC (ADR). Seven analysts rating the company a strong buy, seven analysts rating the company a buy, 2 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell with a consensus target price of $241.86.

About Shire PLC (ADR) (NDAQ:SHPG)

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *